| Literature DB >> 28004258 |
Jean-François Faucher1, Cécile Descotes-Genon2, Bruno Hoen2, Joël Godard3, Sophie Félix4, Sébastien Aubry5, Oleg Blagosklonov6, Frédéric Grenouillet7,8, Marie-Pascale Brientini8,9, Carine Richou8,10, Solange Bresson-Hadni8, Catherine Chirouze2.
Abstract
The prognosis of vertebral alveolar echinococcosis (AE) is poor. We report on the unique outcome of a patient with preexisting liver cirrhosis, in whom a diagnosis of vertebral AE was established on vertebral histopathology (D4 corporectomy in 2010 for paraplegia). Therapeutic drug monitoring of albendazole (ABZ) showed that a low dosage was appropriate. The patient recovered and ABZ withdrawal was decided in 2014, with no relapse 18 months later. In this patient, infection was purely or mainly localized in the dorsal spine, and this may have been favored by liver cirrhosis. A longer follow-up is, however, needed to confirm cure.Entities:
Keywords: Alveolar echinococcosis; Cure; Therapeutic drug monitoring; Vertebral
Mesh：
Substances：
Year: 2016 PMID： 28004258 DOI： 10.1007/s15010-016-0974-z
Source DB: PubMed Journal: Infection ISSN： 0300-8126 Impact factor: 3.553